• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS.

作者信息

Hofman Isabel Juliana F, Mortera-Blanco Teresa, Moura Pedro Luis, Vestlund Johanna, Larsson Sigita Venckute, Elvarsdottir Edda M, Walldin Gunilla, Tobiasson Magnus, Sander Birgitta, Dimitriou Marios, Jacobsen Sten-Eirik W, Woll Petter S, Jädersten Martin, Hellström-Lindberg Eva

机构信息

Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.

Department of Hematology, Karolinska University Hospital, Huddinge, Sweden.

出版信息

Blood Adv. 2022 Aug 23;6(16):4705-4709. doi: 10.1182/bloodadvances.2022007858.

DOI:10.1182/bloodadvances.2022007858
PMID:35728121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9631652/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d852/9631652/8b2b4d8f03d7/advancesADV2022007858f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d852/9631652/8b2b4d8f03d7/advancesADV2022007858f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d852/9631652/8b2b4d8f03d7/advancesADV2022007858f1.jpg

相似文献

1
The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS.SF3B1 突变的骨髓增生异常综合征伴环形铁粒幼细胞（MDS-RS）患者中残留野生型造血干细胞（WT HSPCs）的程度与贫血程度相关。
Blood Adv. 2022 Aug 23;6(16):4705-4709. doi: 10.1182/bloodadvances.2022007858.
2
SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes.SF3B1 突变导致 MAP3K7 剪接异常引起骨髓增生异常综合征贫血。
Proc Natl Acad Sci U S A. 2022 Jan 4;119(1). doi: 10.1073/pnas.2111703119.
3
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.骨髓增生异常综合征中环铁粒幼细胞和SF3B1突变的临床结局：MDS临床研究联盟分析
Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):528-532. doi: 10.1016/j.clml.2018.05.016. Epub 2018 May 26.
4
SF3B1 mutant myelodysplastic syndrome: Recent advances.SF3B1 突变骨髓增生异常综合征：最新进展。
Adv Biol Regul. 2021 Jan;79:100776. doi: 10.1016/j.jbior.2020.100776. Epub 2020 Dec 25.
5
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.新诊断的低危骨髓增生异常综合征患者中环形铁幼粒细胞和 SF3B1 突变评估的真实世界诊断检测模式。
Int J Lab Hematol. 2021 Jun;43(3):426-432. doi: 10.1111/ijlh.13400. Epub 2020 Nov 21.
6
Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.SF3B1 突变性骨髓增生异常综合征中 tRNA 合成酶的剪接改变和细胞质水平作为治疗靶点。
Sci Rep. 2019 Feb 25;9(1):2678. doi: 10.1038/s41598-019-39591-7.
7
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs.患者特异性 MDS-RS iPSCs 定义了 SF3B1 突变 HSPCs 的剪接转录本谱和染色质景观。
Blood Adv. 2022 May 24;6(10):2992-3005. doi: 10.1182/bloodadvances.2021006325.
8
SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.伴有环形铁粒幼细胞的SF3B1突变型骨髓增生异常综合征存在更严重的铁过载及相应的红细胞生成过多。
Leuk Res. 2016 May;44:8-16. doi: 10.1016/j.leukres.2016.02.011. Epub 2016 Feb 27.
9
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts.靶向 EIF2AK1 信号通路可挽救环形铁幼粒细胞 MDS 中 SF3B1 突变的红细胞生成。
Blood Cancer Discov. 2022 Nov 2;3(6):554-567. doi: 10.1158/2643-3230.BCD-21-0220.
10
Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome.探索 SF3B1 突变与骨髓增生异常综合征中环铁幼粒细胞形成之间的机制联系。
Sci Rep. 2022 Aug 26;12(1):14562. doi: 10.1038/s41598-022-18921-2.

引用本文的文献

1
Advances and challenges in the treatment of myelodysplastic syndromes.骨髓增生异常综合征治疗的进展与挑战
Exp Hematol Oncol. 2025 Jun 18;14(1):87. doi: 10.1186/s40164-025-00678-9.
2
Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts.环形铁幼粒细胞性难治性贫血伴原始细胞增多的疾病分类和风险分层中整合基因组和转录组分析的改善
Clin Cancer Res. 2023 Oct 13;29(20):4256-4267. doi: 10.1158/1078-0432.CCR-23-0538.

本文引用的文献

1
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.SF3B1 突变性 MDS 作为一种独特的疾病亚型：来自 MDS 预后国际工作组的建议。
Blood. 2020 Jul 9;136(2):157-170. doi: 10.1182/blood.2020004850.
2
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.芦可替尼治疗低危骨髓增生异常综合征患者的疗效。
N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.
3
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
促红细胞生成素刺激剂治疗低危和中危-1 风险骨髓增生异常综合征的临床疗效和安全性：系统文献评价。
Br J Haematol. 2019 Jan;184(2):134-160. doi: 10.1111/bjh.15707. Epub 2018 Dec 13.
4
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.与年龄和性别匹配的参考人群相比，低危 MDS 患者的健康相关生活质量：一项欧洲白血病网络研究。
Leukemia. 2018 Jun;32(6):1380-1392. doi: 10.1038/s41375-018-0089-x. Epub 2018 Mar 6.
5
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.骨髓增生异常综合征中对促红细胞生成素刺激剂反应的预测模型：来自加拿大骨髓增生异常综合征患者登记处
Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3.
6
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.ITACA：一种新的经过验证的国际红细胞生成刺激剂反应评分系统，进一步提高了先前评分系统的预测能力。
Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.
7
-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.骨髓增生异常综合征伴环形铁粒幼细胞（MDS-RS）中的起始突变靶向淋巴髓系造血干细胞。
Blood. 2017 Aug 17;130(7):881-890. doi: 10.1182/blood-2017-03-776070. Epub 2017 Jun 20.
8
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.促红细胞生成素能显著延迟低危骨髓增生异常综合征未输血患者开始定期输血的时间。
J Intern Med. 2017 Mar;281(3):284-299. doi: 10.1111/joim.12579. Epub 2016 Dec 7.
9
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.骨髓增生异常综合征是由体内罕见而独特的人类癌症干细胞增殖引起的。
Cancer Cell. 2014 Jun 16;25(6):794-808. doi: 10.1016/j.ccr.2014.03.036. Epub 2014 May 15.
10
Clinical and biological implications of driver mutations in myelodysplastic syndromes.骨髓增生异常综合征中驱动突变的临床和生物学意义。
Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.